This HTML5 document contains 210 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q54465171
rdf:type
wikibase:Item
schema:description
scientific article научни чланак 2012年学术文章 tieteellinen artikkeli scienca artikolo article scientific bilimsel makale vitenskapelig artikkel 2012年學術文章 artigo científico (publicado na 2012) επιστημονικό άρθρο bài báo khoa học vetenskaplig artikel мақолаи илмӣ научни чланак 2012年の論文 мақолаи илмӣ מאמר מדעי 2012年學術文章 article científic научна статия 2012年學術文章 vedecký článok บทความทางวิทยาศาสตร์ 2012 ഡിസംബര്‍ 12 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം artículo científico publicado en 2012 2012년 논문 2012年学术文章 artikull shkencor سائنسی مضمون tudományos cikk vědecký článek գիտական հոդված articol științific наукова стаття, опублікована в грудні 2012 artigo científico სამეცნიერო სტატია 2012年学术文章 مقالهٔ علمی article scientifique (publié 2012) artículu científicu articolo scientifico videnskabelig artikel (udgivet 2012) artigo científico (publicado na 2012) مقالة علمية 2012年學術文章 2012年学术文章 научная статья wetenschappelijk artikel naučni članak 2012年學術文章 artykuł naukowy teaduslik artikkel 2012 nî lūn-bûn 2012年学术文章 artikulong pang-agham mokslinis straipsnis 2012年學術文章 vitskapeleg artikkel wissenschaftlicher Artikel ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ
p:P577
wds:Q54465171-873EA152-C6DC-4112-AF01-96672852EFF4
wdt:P577
2012-12-12T00:00:00Z
p:P2860
wds:Q54465171-41B6D131-7E2A-407C-B37A-7112423AFDBA wds:Q54465171-279E4900-35C8-4B17-BB24-060176A4FDCE wds:Q54465171-4FB35F38-4947-4537-B348-1393BB1977D9 wds:Q54465171-4E992F9B-216D-4D0A-A93C-FEE2A584F54E wds:Q54465171-10FB56DD-757B-4101-A7D8-33CB0BF2B0AC wds:Q54465171-16AEDE6E-7103-49E0-872C-886945BDA901 wds:Q54465171-25C6033D-112C-44D2-A8C8-C3B3085A1F40 wds:Q54465171-18992D50-8256-49DE-BE5A-B3ED4C225740 wds:Q54465171-1B8B04F5-2015-4C6E-9F3A-E0D7868D2A1E wds:Q54465171-1FA7F2E2-206B-4293-9886-08A312DAD80E wds:Q54465171-C4847BA3-526B-47AD-97C7-14804404A2BB wds:Q54465171-C530F35D-5548-4895-82C9-803D4E8629DF wds:Q54465171-A08ABF1F-4A76-4BF5-8953-38E6420B88D6 wds:Q54465171-A182D46B-BDDC-4B1F-8E95-2835F1FA07DF wds:Q54465171-A35D2784-B5B9-4209-9143-0D0AD7128FFB wds:Q54465171-E17004C3-9F72-4F77-91FC-681DEC03D6BA wds:Q54465171-E1AEC131-8B98-4C8B-BFC2-C5C689CA4E7D wds:Q54465171-E3D986A4-5D53-41F2-B956-4A37F2B2FD29 wds:Q54465171-D3C9480B-D065-4CE8-B9AC-4C6F3D75FA62 wds:Q54465171-D9F7E36E-8CAB-44FE-A18E-33FEDC627571 wds:Q54465171-754254B7-CA65-4D2E-AECC-03E5E9F0347A wds:Q54465171-7C926658-2289-43A9-AEE1-0B7BB918622A wds:Q54465171-6E3B096E-0263-4DE7-9A0B-D346E3C54547 wds:Q54465171-7423A37F-0DA1-49DD-AA20-627F274A4E4D wds:Q54465171-9ACE1839-11E9-411D-AE0B-3AFDDF17E748 wds:Q54465171-88D718FB-1ED2-4D9E-BE17-9FC908C6E31E wds:Q54465171-E8678A8B-2D4C-4266-B617-3D36361AB2C3
wdt:P2860
wd:Q54600960 wd:Q54376091 wd:Q63365933 wd:Q40477055 wd:Q73308218 wd:Q46828225 wd:Q34199968 wd:Q29547513 wd:Q46522790 wd:Q27860709 wd:Q80408348 wd:Q42788947 wd:Q44547436 wd:Q84661096 wd:Q45000486 wd:Q46825153 wd:Q46127853 wd:Q57578575 wd:Q37155629 wd:Q46579411 wd:Q44902909 wd:Q77331953 wd:Q34743488 wd:Q46580491 wd:Q36962419 wd:Q39785729 wd:Q34601123
p:P2093
wds:Q54465171-71B38BC6-55D9-4BA7-846F-E92362B4D140 wds:Q54465171-6FD65B1C-765F-4BFA-A305-D23E636263DE wds:Q54465171-8B906F1C-9673-4436-A726-5578CCBBACA3 wds:Q54465171-874950AB-49A8-45B2-A9BC-B5323FD545FE wds:Q54465171-95C95316-747C-45F2-9307-94286BE1960D wds:Q54465171-D3BA72CF-01AF-4284-B354-FCAC4268C234 wds:Q54465171-E6A84C2B-8AAA-44ED-801C-9B2882827135 wds:Q54465171-08A83474-CF19-4A13-81E8-BE9EA8AD14C2 wds:Q54465171-182571D8-7261-4ABA-9A20-C33FC5397583 wds:Q54465171-2C600D29-A583-4FA9-8C66-D651277497ED wds:Q54465171-2851DAAC-2DAB-4E30-99D2-8BAC8FA0E91F wds:Q54465171-42EE0A1C-FEE9-4187-A39C-3909CC2E0C87 wds:Q54465171-3809D8A0-D108-4B61-AF58-C1680E36D706 wds:Q54465171-478A899F-CA1F-4F91-92C4-C259712949B4 wds:Q54465171-5DAC2D35-204C-4037-BE9A-1A63DB524C91 wds:Q54465171-EC495CA7-4FB2-46F9-A840-AB348C03D1DC wds:Q54465171-EB9A30AB-F53E-4CC6-AD5B-57A447967FE8 wds:Q54465171-F819601A-3B5F-498E-89E4-4476E8A7227D wds:Q54465171-FA503366-3DB3-4AEC-AB3F-AB86F84F2839 wds:Q54465171-F642BCC4-9E20-42CF-B549-3337F3036D2E wds:Q54465171-FB2D030E-4089-490A-80E2-D26A99B108FB wds:Q54465171-FBE8F8A1-119A-4C59-AEFF-9B4E000B1BE5
wdt:P2093
Véronique Wilson Vincent Houé Alvaro Rodríguez-Lescure Barrett H Childs Kara Laing TRIO/BCIRG 001 investigators Jeferson Vinholes Manuel R Modiano Charles Vogel Robert Coleman Chris Price John Hainsworth Bruce Colwell Eva Juhos Amer Sami Kimberly Bassi Judith C Hugh Tamas Pinter David Walde Pierre Whitlock Louise Provencher Mary-Ann Lindsay
rdfs:label
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
skos:prefLabel
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
schema:name
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
p:P50
wds:Q54465171-0380887F-FCFA-4EC8-9F75-ED52DCAD7F0A wds:Q54465171-461A020D-C63D-47FD-ACEA-C3FEC9C651A7 wds:Q54465171-4A526309-E113-43A8-B989-0302ECE1EDB4 wds:Q54465171-6B6FC5B5-C798-4AA7-8B43-211A4D69A57F wds:Q54465171-2F7413C3-BB26-40E6-B66D-F1A3073FF11B wds:Q54465171-39A739D7-BA3D-4452-94E0-DCC6D6621BE2 wds:Q54465171-8B92B8D9-BBE3-4E1C-8028-2E2A14AAB290 wds:Q54465171-D7C46C24-9DB3-418A-8799-F108C926D642 wds:Q54465171-A4195DA6-14F6-49F3-9FF5-E11A8418DB53
wdt:P50
wd:Q116772906 wd:Q56550967 wd:Q116772907 wd:Q38290512 wd:Q116794157 wd:Q43247711 wd:Q116772912 wd:Q116772909 wd:Q73146120
p:P1476
wds:Q54465171-7E7B099D-F001-4354-A89B-FB3C08C64A03
wdt:P1476
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
p:P304
wds:Q54465171-F1740D4F-7EEF-4B9A-A08D-281E70260DBF
wdt:P304
72-80
p:P31
wds:Q54465171-5FB501D3-A965-41DE-B034-37CDB8190F36
wdt:P31
wd:Q13442814
p:P921
wds:Q54465171-9FAD483B-7ADA-4832-961D-FCFC2DD136FF wds:Q54465171-9B1004DE-68C4-4C42-BAED-820543F107E8 wds:Q54465171-9C002A98-099E-4354-8A1C-E26BA6E9B271
wdt:P921
wd:Q42824827 wd:Q420436 wd:Q18936
p:P698
wds:Q54465171-EE4FF3E0-3DF2-490B-9424-5E1A60454638
wdtn:P698
n11:23246022
wdt:P698
23246022
p:P1433
wds:Q54465171-21B11BB4-40AB-429F-9D41-7FB1826780FB
wdt:P1433
wd:Q13747613
p:P433
wds:Q54465171-B174FE50-73CF-4636-9E80-F9E51729EA2A
p:P478
wds:Q54465171-26BF664D-47C8-4B09-A715-9B8A85A157D6
wdt:P433
1
wdt:P478
14
p:P356
wds:Q54465171-239F9958-51C0-4C12-B832-F9705B62D655
wdtn:P356
n8:S1470-2045(12)70525-9
wdt:P356
10.1016/S1470-2045(12)70525-9